Heparin, heparan sulfate and heparanase in inflammatory reactions

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 823-828

  Li, Jin Ping ^a   Vlodavsky, Israel ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chemokine; Polysaccharide; Proteoglycans; Structure function; Transmigration; Vascular endothelium

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; GLYCOSIDASE; HEPARAN SULFATE; HEPARANASE; HEPARIN; INTERLEUKIN 8; L SELECTIN; PADGEM PROTEIN; PROTEOHEPARAN SULFATE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BURN; CELL MIGRATION; CELL SURFACE; CONFERENCE PAPER; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN INJURY; ULCERATIVE COLITIS; UPREGULATION; VASCULAR ENDOTHELIUM;

AMYLOIDOSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBOHYDRATE SEQUENCE; CHEMOTAXIS, LEUKOCYTE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; GOLGI APPARATUS; HEPARIN; HEPARITIN SULFATE; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70449604674     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0091     Document Type: Conference Paper

References (84)

1. Horner AA. Macromolecular heparin from rat skin. Isolation, characterization, and depolymerization with ascorbate. J Biol Chem 1971; 246: 231-239.
2. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777. (Pubitemid 29449208)
3. Fransson LA, Belting M, Cheng F, et al. Novel aspects of glypican glycobiology. Cell Mol Life Sci 2004; 61: 1016-10124.
4. Cole GJ, Halfter W. Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 1996; 3: 359-371. (Pubitemid 126839141)
5. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-652.
6. Lindahl U. Biosynthesis of Heparin and related polysaccharides. In: Lane DA, Lindahl U, editors. HEPARIN Chemical and Biological Properties, Clinical Applications. First ed. Edward Arnold, London; 1989; 159-189.
7. Lindahl U. Biosynthesis of heparin. Biochem Soc Trans 1990; 18: 803-805.
8. Ledin J, Staatz W, Li JP, et al. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 2004; 279: 42732-42741. (Pubitemid 39372160)
9. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001 Jul; 108: 169-173.
10. Kreuger J, Spillmann D, Li JP, et al. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 2006 Jul 31; 174: 323-327. (Pubitemid 44156762)
11. Lindahl U. Heparan sulfate-protein interactions - a concept for drug design? Thromb Haemost 2007; 98: 109-115.
12. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
13. Lindahl U, Backstrom G, Hook M, et al. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci U S A 1979; 76: 3198-3202.
14. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci U S A 1979; 76: 1218-1222.
15. Lindahl U, Bäckström G, Thunberg L, et al. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A 1980; 77: 6551-6555. (Pubitemid 11219166)
16. Forsberg E, Pejler G, Ringvall M, et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999; 400: 773-776. (Pubitemid 29399539)
17. Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182: 647-656.
18. Jorpes JE, Gardell S. On heparin monosulfuric acid. Journal of Biological Chemistry 1948; 176: 267-275.
19. Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004; 131: 6009-6021. (Pubitemid 40123916)
20. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005; 105: 2745-2764.
21. Skinner R, Abrahams JP, Whisstock JC, et al. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-609. (Pubitemid 27117291)
22. Hashimoto O, Nakamura T, Shoji H, et al. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 1997; 272: 13835-13842. (Pubitemid 27224823)
23. Dowd CJ, Cooney CL, Nugent MA. Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem 1999; 274: 5236-5244. (Pubitemid 129501547)
24. Gingis-Velitski S, Zetser A, Kaplan V, et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004; 279: 44084-44092. (Pubitemid 39390718)
25. Lin X, Wei G, Shi Z, et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol 2000; 224: 299-311. (Pubitemid 30661012)
26. Bullock SL, Fletcher JM, Beddington RS, et al. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 1998; 12: 1894-1906.
27. Ringvall M, Ledin J, Holmborn K, et al. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N- sulfotransferase-1. J Biol Chem 2000; 275: 25926-25930. (Pubitemid 30676630)
28. Li J-P, Gong F, Hagner-McWhirter Å, et al. Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 2003; 278: 28363-28366. (Pubitemid 36935735)
29. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001; 11: 629-634. (Pubitemid 32972028)
30. Coombe DR, Kett WC. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. Cell Mol Life Sci 2005; 62: 410-424.
31. Jastrebova N, Vanwildemeersch M, Rapraeger AC, et al. Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors. J Biol Chem 2006; 281: 26884-26892. (Pubitemid 44401717)
32. Ögren S, Lindahl U. Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 1975; 250: 2690-2697.
33. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802. (Pubitemid 29318614)
34. Hulett MD, Freeman C, Hamdorf BJ, et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803-809. (Pubitemid 29318615)
35. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999; 274: 24153-24160. (Pubitemid 129528462)
36. McKenzie E, Tyson K, Stamps A, et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000; 276: 1170-1177. (Pubitemid 30761379)
37. Zcharia E, Jia J, Zhang X, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 2009; 4: e5181.
38. Levy-Adam F, Miao HQ, Heinrikson RL, et al. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 2003; 308: 885-891. (Pubitemid 36976542)
39. McKenzie E, Young K, Hircock M, et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 2003; 373: 423-435. (Pubitemid 36897845)
40. Nardella C, Lahm A, Pallaoro M, et al. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004; 43: 1862-1873. (Pubitemid 38233249)
41. Abboud-Jarrous G, Atzmon R, Peretz T, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008; 283: 18167-18176.
42. de Mestre AM, Rao S, Hornby JR, et al. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 2005; 280: 35136-35147. (Pubitemid 41532700)
43. Baraz L, Haupt Y, Elkin M, et al. Tumor suppressor p53 regulates heparanase gene expression. Oncogene 2006; 25: 3939-3947. (Pubitemid 43990749)
44. Chen G, Wang D, Vikramadithyan R, et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004; 43: 4971-4977. (Pubitemid 38544450)
45. Sandwall E, Bodevin S, Nasser NJ, et al. Molecular structure of heparan sulfate from spalax: Implications of heparanase and hypoxia. J Biol Chem 2008; 284: 3814-3822.
46. Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 2006; 281: 23804-23811. (Pubitemid 44274156)
47. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-2039. (Pubitemid 44397619)
48. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25: 349-351.
49. Zcharia E, Metzger S, Chajek-Shaul T, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. Faseb J 2004; 18: 252-263. (Pubitemid 38186244)
50. Zcharia E, Zilka R, Yaar A, et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005; 19: 211-221. (Pubitemid 40192578)
51. Zcharia E, Philp D, Edovitsky E, et al. Heparanase regulates murine hair growth. Am J Pathol 2005; 166: 999-1008. (Pubitemid 40524425)
52. Spiegel A, Zcharia E, Vagima Y, et al. Heparanase regulates retention and proliferation of primitive Sca- 1+/c-Kit+/Lin- cells via modulation of the bone marrow microenvironment. Blood 2008; 111: 4934-4943.
53. Li JP, Galvis ML, Gong F, et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005; 102: 6473-6477.
54. Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-136. (Pubitemid 34743473)
55. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
56. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
57. Schenkel AR, Mamdouh Z, Muller WA. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat Immunol 2004; 5: 393-400. (Pubitemid 38500088)
58. Stringer SE, Nelson MS, Gupta P. Identification of an MIP-1alpha -binding heparan sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs. Blood 2003; 101: 2243-2245. (Pubitemid 36302064)
59. Vives RR, Sadir R, Imberty A, et al. A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. Biochemistry 2002; 41: 14779-14789.
60. Najjam S, Mulloy B, Theze J, et al. Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites. Glycobiology 1998; 8: 509-516. (Pubitemid 28282631)
61. Spillmann D, Witt D, Lindahl U. Defining the Interleukin- 8-binding Domain of Heparan Sulfate. J Biol Chem 1998; 273: 15487-15493. (Pubitemid 28298157)
62. Salek-Ardakani S, Arrand JR, Shaw D, et al. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood 2000; 96: 1879-1888. (Pubitemid 30662112)
63. Norgard-Sumnicht K, Varki A. Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J Biol Chem 1995; 270: 12012-12024.
64. Luo J, Kato M, Wang H, et al. Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J Cell Biochem 2001; 80: 522-531. (Pubitemid 32127467)
65. Tanaka Y, Kimata K, Wake A, et al. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J Exp Med 1996; 184: 1987-1997. (Pubitemid 26404488)
66. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994; 4: 394-400. (Pubitemid 2085143)
67. Axelsson J, Norrman G, Malmstrom A, et al. Initiation of acute pancreatitis by heparan sulphate in the rat. Scand J Gastroenterol 2008; 43: 480-489.
68. Wang L, Fuster M, Sriramarao P, et al. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine- mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6: 902-910. (Pubitemid 43090445)
69. Rashid RM, Lee JM, Fareed J, et al. In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice. Immunol Invest 2007; 36: 183-201.
70. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
71. Davidson BL, Geerts WH, Lensing AW. Low-dose heparin for severe sepsis. N Engl J Med 2002; 347: 1036-1037.
72. Day R, Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-65. (Pubitemid 29304311)
73. Hoppensteadt D, Fareed J, Klein AL, et al. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol 2008; 102: 842-846.
74. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329: 90-95. (Pubitemid 23188822)
75. Torkvist L, Thorlacius H, Sjoqvist U, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328. (Pubitemid 29462307)
76. Saliba MJ, Jr. Heparin in the treatment of burns: a review. Burns 2001; 27: 349-358.
77. Edovitsky E, Lerner I, Zcharia E, et al. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 2006; 107: 3609-3616.
78. Waterman M, Ben-Izhak O, Eliakim R, et al. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 2007; 20: 8-14. (Pubitemid 44967944)
79. Yang Y, Macleod V, Miao HQ, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 282: 13326-13333. (Pubitemid 47100527)
80. Li RW, Freeman C, Yu D, et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 1590-1600. (Pubitemid 351847512)
81. Gong F, Jemth P, Escobar Galvis ML, et al. Processing of macromolecular heparin by heparanase. J Biol Chem 2003; 278: 35152-35158.
82. Pikas DS, Li JP, Vlodavsky I, et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-18777. (Pubitemid 28366261)
83. Escobar Galvis ML, Jia J, Zhang X, et al. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 2007; 3: 773-778. (Pubitemid 350126870)
84. Parish CR. Heparan sulfate and inflammation. Nat Immunol 2005; 6: 861-862.